33 related articles for article (PubMed ID: 38760047)
1. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case-control study.
Su J; Chen P; Yang Y; Gao Z; Bi Z; Feng M
BMJ Open; 2024 May; 14(5):e082484. PubMed ID: 38760047
[TBL] [Abstract][Full Text] [Related]
2. Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease.
Seethapathy H; Mistry K; Sise ME
Immunol Rev; 2023 Sep; 318(1):61-69. PubMed ID: 37482912
[TBL] [Abstract][Full Text] [Related]
3. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Kanbay M; Copur S; Siriopol D; Yildiz AB; Berkkan M; Popa R; Hasbal NB; Ortiz A; Perazella MA
Clin Kidney J; 2023 May; 16(5):817-826. PubMed ID: 37151409
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
5. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis.
Kanbay M; Yildiz AB; Siriopol D; Vehbi S; Hasbal NB; Kesgin YE; Celayir M; Selcukbiricik F; Covic A; Perazella MA
Int Urol Nephrol; 2023 Apr; 55(4):1025-1032. PubMed ID: 36282399
[TBL] [Abstract][Full Text] [Related]
7. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
[TBL] [Abstract][Full Text] [Related]
8. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S; Short SAP; Sise ME; Prosek JM; Madhavan SM; Soler MJ; Ostermann M; Herrmann SM; Abudayyeh A; Anand S; Glezerman I; Motwani SS; Murakami N; Wanchoo R; Ortiz-Melo DI; Rashidi A; Sprangers B; Aggarwal V; Malik AB; Loew S; Carlos CA; Chang WT; Beckerman P; Mithani Z; Shah CV; Renaghan AD; Seigneux S; Campedel L; Kitchlu A; Shin DS; Rangarajan S; Deshpande P; Coppock G; Eijgelsheim M; Seethapathy H; Lee MD; Strohbehn IA; Owen DH; Husain M; Garcia-Carro C; Bermejo S; Lumlertgul N; Seylanova N; Flanders L; Isik B; Mamlouk O; Lin JS; Garcia P; Kaghazchi A; Khanin Y; Kansal SK; Wauters E; Chandra S; Schmidt-Ott KM; Hsu RK; Tio MC; Sarvode Mothi S; Singh H; Schrag D; Jhaveri KD; Reynolds KL; Cortazar FB; Leaf DE;
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625513
[TBL] [Abstract][Full Text] [Related]
10. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.
Koks MS; Ocak G; Suelmann BBM; Hulsbergen-Veelken CAR; Haitjema S; Vianen ME; Verhaar MC; Kaasjager KAH; Khairoun M
PLoS One; 2021; 16(6):e0252978. PubMed ID: 34101756
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.
Isik B; Alexander MP; Manohar S; Vaughan L; Kottschade L; Markovic S; Lieske J; Kukla A; Leung N; Herrmann SM
Kidney Int Rep; 2021 Apr; 6(4):1022-1031. PubMed ID: 33912752
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
Shimamura Y; Watanabe S; Maeda T; Abe K; Ogawa Y; Takizawa H
Clin Exp Nephrol; 2021 May; 25(5):479-487. PubMed ID: 33471239
[TBL] [Abstract][Full Text] [Related]
14. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
Cortazar FB; Kibbelaar ZA; Glezerman IG; Abudayyeh A; Mamlouk O; Motwani SS; Murakami N; Herrmann SM; Manohar S; Shirali AC; Kitchlu A; Shirazian S; Assal A; Vijayan A; Renaghan AD; Ortiz-Melo DI; Rangarajan S; Malik AB; Hogan JJ; Dinh AR; Shin DS; Marrone KA; Mithani Z; Johnson DB; Hosseini A; Uprety D; Sharma S; Gupta S; Reynolds KL; Sise ME; Leaf DE
J Am Soc Nephrol; 2020 Feb; 31(2):435-446. PubMed ID: 31896554
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREAtinine Measurement project.
Su G; Trevisan M; Ishigami J; Matsushita K; Stålsby Lundborg C; Carrero JJ
Nephrol Dial Transplant; 2020 Nov; 35(11):1894-1900. PubMed ID: 31219575
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity.
Volarevic V; Djokovic B; Jankovic MG; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N
J Biomed Sci; 2019 Mar; 26(1):25. PubMed ID: 30866950
[TBL] [Abstract][Full Text] [Related]
18. Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators.
Van Calster B; Wynants L; Verbeek JFM; Verbakel JY; Christodoulou E; Vickers AJ; Roobol MJ; Steyerberg EW
Eur Urol; 2018 Dec; 74(6):796-804. PubMed ID: 30241973
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
